Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article

Faeq R. Kukhon, Emir Festic

Research output: Contribution to journalReview articlepeer-review


Community-acquired pneumonia is still a major cause of morbidity and mortality worldwide. Since the inflammatory response induced by the immune system is often a major contributor to the lung injury, it becomes reasonable to assess the potential benefit of anti-inflammatory agents in treating community-acquired pneumonia. The role of corticosteroids as adjunct anti-inflammatory agents in treating community-acquired pneumonia is still controversial. Several studies have assessed the benefit of their use in patients with community-acquired pneumonia. In most of those studies, the route of corticosteroids administration was systemic. The aim of this article is to provide a concise review of the role of corticosteroids in treating community-acquired pneumonia when administered via inhalational route, with the potential benefit of avoiding systemic side effects of corticosteroids while exerting the same anti-inflammatory effects on the lungs. Conclusion: the use of inhaled corticosteroids may be of benefit in certain patient subsets with community-acquired pneumonia. Further randomized controlled trials are needed for better determination of such patient subsets.

Original languageEnglish (US)
JournalMedical sciences (Basel, Switzerland)
Issue number2
StatePublished - May 23 2021


  • community-acquired pneumonia
  • inhaled corticosteroids
  • long-acting beta agonists
  • systemic corticosteroids

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia: A Review Article'. Together they form a unique fingerprint.

Cite this